Related Experiment Video

Updated: Jun 10, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

Update on the clinical development of cangrelor

Masafumi Ueno1, José Luis Ferreiro, Dominick J Angiolillo

  • 1Department of Medicine, Division of Cardiology, University of Florida College of Medicine-Jacksonville, Shands Jacksonville, 655 West 8th Street, Jacksonville, FL 32209, USA.

Expert Review of Cardiovascular Therapy
|July 31, 2010
PubMed

Insights

Cangrelor, an intravenous antiplatelet drug, shows potent P2Y12 inhibition but failed to demonstrate significant clinical benefit in recent Phase III trials for cardiovascular atherothrombotic disease.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Thrombosis Research

Background:

  • Dual oral antiplatelet therapy (aspirin and clopidogrel) is standard for acute coronary syndrome and percutaneous coronary intervention.
  • Clopidogrel has limitations including variable response, drug interactions, and slow onset.
  • Novel antiplatelet agents are needed to overcome clopidogrel's limitations.

Purpose of the Study:

  • To review the pharmacologic properties of cangrelor.
  • To discuss the clinical development of cangrelor.
  • To evaluate cangrelor's potential in treating cardiovascular atherothrombotic disease.

Main Methods:

  • Overview of cangrelor's mechanism of action as a reversible P2Y12 receptor inhibitor.
  • Review of Phase III clinical trial data regarding cangrelor's efficacy and safety.
  • Analysis of cangrelor's pharmacokinetic and pharmacodynamic profile.

Main Results:

  • Cangrelor demonstrates rapid, potent, and reversible inhibition of ADP-induced platelet aggregation.
  • Large-scale Phase III trials did not show significant clinical benefit for cangrelor on primary endpoints.
  • Despite promising pharmacology, clinical outcomes did not meet expectations.

Conclusions:

  • Cangrelor possesses favorable pharmacological properties for antiplatelet therapy.
  • Current clinical evidence suggests cangrelor may not offer significant advantages over existing therapies.
  • Further research may be needed to define cangrelor's role in specific patient populations.

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...